The clinical efficacy and safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials

In conclusion, while SGLT2 inhibitors show promise in reducing hospitalization for HF post-AMI, their impact on mortality and safety outcomes necessitates further investigation. This underscores the need for larger, more diverse RCTs to fully illustrate their role and timing of initiation in AMI management. An individualized approach based on risk assessment should guide their use in the post-AMI population.